Risk Breakdown
Financial Exposure
Governance
Double Materiality
Supply Chain
Material Risks
ESG Targets & Commitments
| Topic | Target / Metric | Status |
|---|---|---|
| Human Rights in Supply Chain | HR clauses in all contracts | Commitment |
AI Risk Summary
**Financial Risk Summary – SMS Pharmaceuticals Limited** SMS Pharmaceuticals faces critical compliance exposure under SEBI BRSR Core Expansion requirements, with a maximum estimated remediation cost of ₹1–5 crore and material delisting risk if disclosure and governance gaps persist. The company's maximal compliance risk score (10.0/10) and unknown EPR applicability status (6.5/10 exposure) represent the largest financial vulnerabilities; pharmaceutical manufacturers typically face mandatory Extended Producer Responsibility obligations under plastic waste rules, with potential penalties of ₹25,000–₹1 lakh per violation plus product recall costs. The absence of reported Scope 1 and 2 emissions data—unusual for a ₹783 crore API manufacturer—signals either incomplete environmental accounting or deliberate non-disclosure, both violations triggering SEBI enforcement action and reputational capital loss. Priority actions: immediately clarify EPR statutory status, quantify actual emissions (critical for carbon pricing exposure under emerging India CCTS mechanisms at ₹600–900/tonne), and remediate all BRSR governance discrepancies to mitigate del
Source: SMS PHARMACEUTICALS LIMITED BRSR Filing, FY 2024-2025. Derived from the company's own public disclosures. Not investment advice or a regulatory determination.